Table 5.

Comparison of incidence of selected nonhematological toxicities among patients with and without DS randomized to MTX regimens

PO MTXIV MTXDS patientsNon-DS patients
DS, %Non-DS, %PDS, %Non-DS, %PPO, %IV, %PPO, %IV, %P
ALT (grades 3/4)             
 IM #1 16.3 17.1 .70 12.9 7.6 .48 16.3 12.9 .69 17.1 7.6 <.001 
 IM #2 7.5 13.9 .40 6.9 8.6 .84 7.5 6.9 .66 13.9 8.6 .001 
Infection with neutropenia (grades 3/4)             
 IM #1 4.7 2.6 .43 2.3 .39 4.7 .22 2.6 2.3 .66 
 IM #2 5.0 3.9 .72 1.5 .51 .22 3.9 1.5 .001 
Leukoencephalopathy (all grades)             
 IM #1 0.2 .96 0.4 .94 — 0.2 0.4 .61 
 IM #2 0.1 .84 0.5 .93 — 0.1 0.5 .25 
Mucositis (grades 3/4)             
 IM #1 2.3 0.6 .30 29.0 3.4 <.001 2.3 29.0 .004 0.6 3.4 <.001 
 IM #2 10 0.6 <.001 27.6 4.1 <.001 10 27.6 .13 0.6 4.1 <.001 
Seizures (all grades)             
 IM #1 0.1 .83 3.2 1.2 .55 3.2 .24 0.1 1.2 .02 
 IM #2 0.1 .84 0.8 .89 — 0.1 0.8 .05 
PO MTXIV MTXDS patientsNon-DS patients
DS, %Non-DS, %PDS, %Non-DS, %PPO, %IV, %PPO, %IV, %P
ALT (grades 3/4)             
 IM #1 16.3 17.1 .70 12.9 7.6 .48 16.3 12.9 .69 17.1 7.6 <.001 
 IM #2 7.5 13.9 .40 6.9 8.6 .84 7.5 6.9 .66 13.9 8.6 .001 
Infection with neutropenia (grades 3/4)             
 IM #1 4.7 2.6 .43 2.3 .39 4.7 .22 2.6 2.3 .66 
 IM #2 5.0 3.9 .72 1.5 .51 .22 3.9 1.5 .001 
Leukoencephalopathy (all grades)             
 IM #1 0.2 .96 0.4 .94 — 0.2 0.4 .61 
 IM #2 0.1 .84 0.5 .93 — 0.1 0.5 .25 
Mucositis (grades 3/4)             
 IM #1 2.3 0.6 .30 29.0 3.4 <.001 2.3 29.0 .004 0.6 3.4 <.001 
 IM #2 10 0.6 <.001 27.6 4.1 <.001 10 27.6 .13 0.6 4.1 <.001 
Seizures (all grades)             
 IM #1 0.1 .83 3.2 1.2 .55 3.2 .24 0.1 1.2 .02 
 IM #2 0.1 .84 0.8 .89 — 0.1 0.8 .05 

—, not calculated; ALT, alanine aminotransferase.

or Create an Account

Close Modal
Close Modal